Aim. To study comparative influence of furosemide and torasemide on heart rhythm variability in patients with chronic heart failure of ischemic origin. Methods. The study included 48 patients (29 males and 19 females) with ischemic heart disease complicated by chronic
Aim. To explore the features of insulin resistance variations in overweight and obese patients with metabolic syndrome treated with moxonidine and combination of moxonidine and ivabradine.Methods. The study included 30 patients with metabolic syndrome, who were overweight (body mass index 26.9±0.2 kg/m2) and 30 patients with metabolic syndrome and obesity (BMI 34.2±0.3). Control group included 17 healthy volunteers matched with patients by age and sex. Patients with metabolic syndrome and excessive body weight received moxonidine twice daily in average daily dose of 0.58±0.07 mg. Patients with metabolic syndrome and obesity received moxonidine twice daily in average daily dose of 0.52±0.04 mg and ivabradine twice daily in average daily dose of 13.7±1.1 mg. Biochemical blood tests (insulin, C-peptide, glucose, glycated hemoglobin serum levels) were performed in all patients.Results.Patients with metabolic syndrome and obesity tended to increase insulin resistance, compared to individuals with metabolic syndrome and excessive body weight. In overweight patients with metabolic syndrome treated with moxonidine, a trend for lower insulin resistance, accompanied by a decrease of insulin, C-peptide, glycosylated hemoglobin, glucose levels and homeostasis model assessment-estimated insulin resistance (HOMA-IR) index by 7.1, 2.0, 5.0, 7.3 and 12.2% respectively was discovered. Combination therapy with moxonidine and ivabradine in patients with metabolic syndrome and obesity leaded to a statistically significant improvement of insulin resistance, accompanied by a decrease of insulin levels, glucose, C-peptide, and glycated hemoglobin by 16.7%, 12.3% (pConclusion. In patients with metabolic syndrome, deepening of insulin resistance on the background of increased sympathetic activity is associated with higher grades of obesity. Combination therapy with moxonidine and ivabradine in patients with metabolic syndrome and obesity leads to a significant improvement in insulin resistance due to the additional sympatholytic effect.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.